First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab

被引：0

作者：

Vaglica, M. ^{[1
]}

Lambertini, M. ^{[2
]}

Ferreira, A. ^{[3
]}

Poggio, F. ^{[2
]}

Puglisi, F. ^{[4
]}

Sottotetti, F. ^{[5
]}

Montemurro, F. ^{[6
]}

Poletto, E. ^{[4
]}

Pozzi, E. ^{[5
]}

Risi, E. ^{[7
]}

Lai, A. ^{[8
]}

Zanardi, E. ^{[9
]}

Sini, V. ^{[10
]}

Ziliani, S. ^{[11
]}

Minuti, G. ^{[12
]}

Mura, S. ^{[13
]}

Grasso, D. ^{[14
]}

Ferrarini, I. ^{[15
]}

Pronzato, P. ^{[2
]}

Del Mastro, L. ^{[1
]}

机构：

[1] IRCCS AOU San Martino IST, Med Oncol, UO Sviluppo Terapie Innovat, Genoa, Italy

[2] IRCCS AOU San Martino IST, UO Oncol Med 2, Genoa, Italy

[3] Hosp Santa Maria, Inst Med Mol, Lisbon, Portugal

[4] Univ Hosp, Oncol, Udine, Italy

[5] Fdn Maugeri IRCCS, Med Oncol, Pavia, Italy

[6] Fdn Piemonte Oncol, Ist Candiolo IRCCS, Unit Invest Clin Oncol, Candiolo Torino, Italy

[7] Univ Roma La Sapienza, Radiol Oncol & Human Pathol, Oncol Unit B, I-00185 Rome, Italy

[8] Azienda Osped Univ, Med Oncol, Sassari, Italy

[9] IRCCS AOU San Martino IST, Med Oncol, Clin Oncol Med, Genoa, Italy

[10] Univ Roma La Sapienza, St Andrea Hosp, Oncol, I-00185 Rome, Italy

[11] Osped San Paolo, Med Oncol, Savona, Italy

[12] Civil Hosp, Ist Tumori Toscano, Med Oncol, Livorno, Italy

[13] Osped Santissima Annunziata, Oncol, Sassari, Italy

[14] IRCCS San Matteo Univ Hosp Fdn, Med Oncol, Pavia, Italy

[15] Azienda Osped Univ Pisana, Polo Oncol, Pisa, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30813-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1863

引用

页码：S286 / S286

页数：1

共 50 条

[21] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
Sotelo, Miguel J.
Manso, Luis
Garcia Saenz, Jose Angel
Ciruelos, Eva M.
Moreno, Fernando
Mendiola, Cesar
Callata, Hector
Ghanem, Ismael
Cabezas, Santiago
Gonzalez-Larriba, Jose-Luis
Diaz Rubio, Eduardo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[22] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
Baez-Vallecillo, L.
Raghavendra, A. Singareeka
Hess, K.
Moulder, S. L.
Tripathy, D.
Valero, V.
Murthy, R. K.
CANCER RESEARCH, 2017, 77
[23] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
Mamounas, Eleftherios P.
Geyer, Charles E., Jr.
Huang, Chiun-Sheng
Mano, Max S.
Loibl, Sibylle
Untch, Michael
Wolmark, Norman
Rastogi, Priya
Schneeweiss, Andreas
Redondo, Andres
Fischer, Hans H.
Jacot, William
Conlin, Alison K.
Arce-Salinas, Claudia
Wapnir, Irene L.
Jackisch, Christian
DiGiovanna, Michael P.
Fasching, Peter A.
Crown, John P.
Wuelfing, Pia
Shao, Zhimin
Caremoli, Elena Rota
Wu, Haiyan
Lam, Lisa H.
Tesarowski, David
Smitt, Melanie
Douthwaite, Hannah
Singel, Stina M.
von Minckwitz, Gunter
SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
[24] A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
Church, David N.
Price, Chris G. A.
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 557 - 570
[25] HER2-positive metastatic Breast Cancer Trastuzumab Emtansine: First Choice for the Second Line
不详
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 744 - 744
[26] First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy
Rier, Hanah N.
Levin, Mark-David
van Rosmalen, Joost
Bos, Monique M. E. M.
Drooger, Jan C.
de Jong, Paul
Portielje, Johanneke E. A.
Elsten, Elisabeth M. P.
ten Tije, Albert-Jan
Sleijfer, Stefan
Jager, Agnes
ONCOLOGIST, 2017, 22 (08): : 901 - 909
[27] Clinical outcomes of pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer
Zhou, J.
Wu, X.
Chen, J.
Bian, L.
Zhang, S.
Jiang, Z.
Wang, T.
ANNALS OF ONCOLOGY, 2023, 34 : S371 - S372
[28] Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer
Hanker, Lars Christian
Foerster, Frank
Schroeder, Jan
Grafe, Andrea
Hitschold, Thomas
Hesse, Tobias
Lattrich, Claus Richard
Rody, Achim
ANTICANCER RESEARCH, 2020, 40 (07) : 3973 - 3981
[29] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
Chan, A.
Yamamoto, D.
Bell, R.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[30] Trastuzumab emtansine in HER2-positive metastatic breast cancer
Montemurro, Filippo
LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697

← 1 2 3 4 5 →